J. Pearlberg

发表

Kinase requirements in human cells: I. Comparing kinase requirements across various cell types

John G Doench, Yanhui Hu, J. Doench, 2008, Proceedings of the National Academy of Sciences.

Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.

Ronnie J Winfrey, Jonathan E. Foley, Jeffry D. Sander, 2008, Molecular cell.

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

G. MacBeath, H. Hirte, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Biomedically Enriched Collection of 7000 Human ORF Clones

Yanhui Hu, Bernhard Korn, Dietmar Hoffmann, 2008, PloS one.

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

C. Mermel, P. Jänne, Bruce E. Johnson, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Targeted mutagenesis in zebrafish using customized zinc-finger nucleases

Jonathan E. Foley, Morgan L. Maeder, J. Joung, 2009, Nature Protocols.

A common trans-acting factor is involved in transcriptional regulation of neurotransmitter genes by cyclic AMP

S. Hyman, Young-Sun Lin, Y. S. Lin, 1988, Molecular and cellular biology.

An AP-2 element acts synergistically with the cyclic AMP- and phorbol ester-inducible enhancer of the human proenkephalin gene.

S. Hyman, M. Comb, J. Pearlberg, 1989, Molecular and cellular biology.

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.

G. MacBeath, P. Goss, V. Semiglazov, 2014 .

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET

E. D. de Vries, W. D. den Dunnen, J. Gietema, 2015, The Journal of Nuclear Medicine.

Deleterious Effects of Hepatitis Delta Virus Replication on Host Cell Proliferation

Yu-Tseung Liu, D. Ganem, J. Pearlberg, 2001, Journal of Virology.

Let's get americans back to work again

A. Chandra, J. Pearlberg, A. Karnal, 2020, Contemporary Clinical Trials Communications.

Contact with a component of the polymerase II holoenzyme suffices for gene activation

Pamela Reinagel, A. Barberis, M. Ptashne, 1995, Cell.

Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription.

H. Goodman, N. Mermod, M. Comb, 1988, The EMBO journal.

GAL11P: A yeast mutation that potentiates the effect of weak GAL4-derived activators

M. Ptashne, J. Pearlberg, H. Himmelfarb, 1990, Cell.

Protein expression clone repositories for functional proteomics.

Joshua LaBaer, J. LaBaer, J. Pearlberg, 2004, Current opinion in chemical biology.

Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells

M. Grace, K. Münger, D. Grueneberg, 2008, Proceedings of the National Academy of Sciences.

Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines

D. Grueneberg, E. Harlow, Wenliang Li, 2008, Proceedings of the National Academy of Sciences.

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

P. Jänne, N. Hanna, D. Tenen, 2005 .

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

P. Jänne, N. Hanna, D. Tenen, 2005, Journal of the National Cancer Institute.

Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells.

John G Doench, J. Doench, J. LaBaer, 2005, Cold Spring Harbor symposia on quantitative biology.

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

G. Shapiro, C. Arteaga, D. Cho, 2016, Clinical Cancer Research.

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy

L. Zou, J. LaBaer, E. Harlow, 2011, Proceedings of the National Academy of Sciences.

Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab

R. Advani, S. Mercadal, J. Sancho, 2016 .

An AP-2 element acts synergistically with the cyclic AMP- and phorbol ester-inducible enhancer of the human proenkephalin gene

J. Pearlberg, H. Goodman, S. Hyman, 1989 .

246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS.

L. Sequist, G. MacBeath, J. Pearlberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.

L. Sequist, D. Jackman, J. Pearlberg, 2012 .

FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.

J. Pearlberg, L. Brail, N. Fowler, 2016 .

Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors

R. Sullivan, J. Wolchok, A. Tolcher, 2017 .

A Commontrans-Acting Factor IsInvolved inTranscriptional Regulation ofNeurotransmitter GenesbyCyclic AMP

Young-Sun Lin, M. Comb, J. Pearlberg, 1988 .

A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers.

W. Korn, J. Pearlberg, B. O'Neil, 2014 .

A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.

J. Soria, A. Adjei, G. Dy, 2013 .